Sign In
Buy IDYA
$28.40
+0.530 (+1.90%)
At Close: Jun 03, 2026
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
03:28am, Friday, 02'nd Jan 2026
Shares of IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the sixteen analysts that are covering the firm, Marketbeat.com reports. One a
Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trial Topline data, including median PFS, are expected in 1Q 2026 to support a potential a
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
06:00am, Wednesday, 10'th Dec 2025
Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026 Targeting to present preclinical data detailing pharmacologic profile and evidence of anti-tumor activity in solid tum
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
07:00pm, Thursday, 04'th Dec 2025
BEIJING--(BUSINESS WIRE)-- #Biocytogen--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncolo
IDEAYA Biosciences, Inc. $IDYA Stock Position Reduced by Fisher Asset Management LLC
04:38am, Thursday, 04'th Dec 2025
Fisher Asset Management LLC trimmed its position in IDEAYA Biosciences, Inc. (NASDAQ: IDYA) by 4.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Comm
IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
05:43pm, Tuesday, 02'nd Dec 2025
IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at approximately 30%, 46%, and 27%, respectively Deep and durable regressions observ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:00am, Friday, 28'th Nov 2025
SOUTH SAN FRANCISCO, Calif. , Nov. 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap
Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away
04:58pm, Tuesday, 25'th Nov 2025
Ideaya Biosciences, Inc. is a precision oncology company with a robust pipeline, highlighted by lead asset darovasertib for uveal melanoma. IDYA's darovasertib shows promising Phase 2 results and mult
Creative Planning Boosts Stake in IDEAYA Biosciences, Inc. $IDYA
03:57am, Tuesday, 25'th Nov 2025
Creative Planning boosted its stake in IDEAYA Biosciences, Inc. (NASDAQ: IDYA) by 99.4% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 121,684 shares of the
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
06:00am, Monday, 24'th Nov 2025
SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted thera
IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2025 SMID Cap Biopharma Call Series Transcript
07:06pm, Thursday, 06'th Nov 2025
IDEAYA Biosciences, Inc. ( IDYA ) Citi's 2025 SMID Cap Biopharma Call Series November 6, 2025 12:00 PM EST Company Participants Yujiro Hata - Founder, President, CEO & Director Conference Call Partici
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
06:00am, Tuesday, 04'th Nov 2025
Phase 2/3 trial (OptimUM-02) of the darovasertib/crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM) to report median PFS data by year-end 2025 to 1Q 2026; on track to comple
Oppenheimer Asset Management Inc. Buys 2,227 Shares of IDEAYA Biosciences, Inc. $IDYA
04:03am, Monday, 03'rd Nov 2025
Oppenheimer Asset Management Inc. raised its stake in IDEAYA Biosciences, Inc. (NASDAQ: IDYA) by 19.3% during the second quarter, according to its most recent disclosure with the Securities and Exchan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:00am, Friday, 31'st Oct 2025
SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap
